Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Blood (2025) 146 (Supplement 1): 2332.

https://doi.org/10.1182/blood-2025-2332

Published: 2025

Journal Articles

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan, Sarah Parker, Prashant Singh, Megan Schaefer, Kristina Slemmer, Kimberly Celotto, Ian Lund, Hailey Battaglia, Annmarie Nowak, Linda Lutgen, Saeed Daneshmandi, Kenan Onel, Philip McCarthy, Nikhil Munshi, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 7469.

https://doi.org/10.1182/blood-2025-7469

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma

Blood (2025) 146 (Supplement 1): 1032.

https://doi.org/10.1182/blood-2025-1032

Published: 2025

Journal Articles

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Rajib Shome, Srikanth Talluri, Diana Cirstea, Rie Matsubara, Farah Rexha, Advait Joshi, Andrew Yee, Nikhil Munshi, Mehmet Samur, Noopur Raje

Blood (2025) 146 (Supplement 1): 3952.

https://doi.org/10.1182/blood-2025-3952

Published: 2025

Journal Articles

Modeling del(17p) in multiple myeloma for molecular and functional characterization

Yuanyuan Jin, Jessica Encinas Mayoral, Anaïs Schavgoulidze, Jian Cui, Ludovica Ganino, Pietro Folino, Anil Aktas-Samur, Mehmet Samur, Mariateresa Fulciniti, Nikhil Munshi

Blood (2025) 146 (Supplement 1): 3941.

https://doi.org/10.1182/blood-2025-3941

Published: 2025

Journal Articles

Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma

Rajib Shome, Mehmet Samur, Srikanth Talluri, Rie Matsubara, Advait Joshi, Farah Rexha, Diana Cirstea, Andrew Yee, Nikhil Munshi, Noopur Raje

Blood (2025) 146 (Supplement 1): 5735.

https://doi.org/10.1182/blood-2025-5735

Published: 2025

Journal Articles

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

Rao Prabhala, Lakshmi Bhavani Potluri, Srikanth Talluri, Hannah Seah, Vaishnavi Bade, Sahan Vangala, Mehmet Samur, Sarah Nikiforow, Alejandro Alonso, Shuntaro Ikegawa, Sinead Dolan, David Pearson, Pedro Milanez-Almeida, Jennifer Mataraza, Jerome Ritz, Dexiu BU, Marc Credi, Adam Sperling, Nikhil Munshi

Blood (2025) 146 (Supplement 1): 5713.

https://doi.org/10.1182/blood-2025-5713

Published: 2025

Journal Articles

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Jackson Smith, Mehmet Samur, Srikanth Talluri, Domenico Maisano, Michela Cumerlato, Charlotte Royer, Fatima Zohura, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Nikhil Munshi, Raphael Szalat

Blood (2025) 146 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2025-3923

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos, Mehmet Samur, Sheri Skerget, Holly Lee, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Daniel Penaherrera, Herve Avet-Loiseau, Jonathan Keats, Nikhil Munshi, Niels Weinhold, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 2163.

https://doi.org/10.1182/blood-2025-2163

Published: 2025

Journal Articles

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

Anna Besschetnova, Francesco Ladisa, Anais Schavgoulidze, Shuhui Deng, Eugenio Morelli, Mehmet Samur, Lucy Ort, Christopher Nardone, Xin Gu, Mariateresa Fulciniti, Nikhil Munshi

Blood (2025) 146 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2025-2147

Published: 2025

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

Jooeun Bae, Shuichi Kitayama, Zach Herbert, Laurence Daheron, Keiji Kurata, Derin B. Keskin, Kenneth Livak, Shuqiang Li, Mubin Tarannum, Rizwan Romee, Mehmet Samur, Nikhil C. Munshi, Shin Kaneko, Jerome Ritz, Kenneth C. Anderson

Blood (2024) 143 (10): 895–911.

https://doi.org/10.1182/blood.2023020528

Published: 2024

Includes: Supplemental data

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Blood (2019) 134 (Supplement_1): 4370.

https://doi.org/10.1182/blood-2019-127362

Published: 2019

Journal Articles

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Alejandra Ortiz-Ruiz, BSc, Yanira Ruiz-Heredia, Mehmet Samur, PhD, Pedro Aguilar-Garrido, Maria Luz Morales, Antonio Valeri, PhD, Almudena Garcia-Ortiz, PhD, Santiago Barrio, PhD, Carmen Bárcena, Rosa Maria Garcia-Martin, Vanesa Garrido, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD, María Teresa Cedena, Joaquin Martinez-Lopez, MD PhD, Maria Linares, PhD, Miguel Gallardo, PhD

Blood (2019) 134 (Supplement_1): 4408.

https://doi.org/10.1182/blood-2019-123950

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies

Genomic determinants and differences of primary and secondary plasma cell leukemia

The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma

Immune aging and macrophage inhibitory factor (MIF) – mediated stromal rewiring drives pre-malignant evolution in smoldering multiple myeloma

Modeling del(17p) in multiple myeloma for molecular and functional characterization

Deciphering the role of EP300 in maintaining the enhancer landscape and lineage-specific epigenetic vulnerability in multiple myeloma

Functional fitness of CAR-T cells in the bone marrow following anti-BCMA durcabtagene autoleucel (PHE885) therapy correlate with prolonged PFS in RRMM

Single-cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms, immune interactions and altered clonal and polyclonal plasma cell phenotypes

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Downregulation of midnolin mediating non-ubiquitin protein degradation and its role in myelomagenesis.

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ + T cells targeting multiple myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker

Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only